MAPK1/MAPK3 (Ab-205/222) Antibody

What are MAPK1/MAPK3 proteins and what cellular functions do they regulate?

MAPK1 (ERK2) and MAPK3 (ERK1) are serine/threonine kinases that function as essential components of the MAP kinase signal transduction pathway. These proteins participate in a signaling cascade that mediates diverse biological functions including cell growth, adhesion, survival, and differentiation through the regulation of transcription, translation, and cytoskeletal rearrangements . Approximately 160 substrates have been discovered for ERKs, many localized in the nucleus and participating in transcription regulation, while others are found in the cytosol and other cellular organelles responsible for processes such as translation and mitosis . MAPK1/MAPK3 are also involved in initiating and regulating meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating various transcription factors .

What applications is the MAPK1/MAPK3 (Ab-205/222) Antibody validated for?

The MAPK1/MAPK3 (Ab-205/222) Antibody has been validated for the following research applications:

• Western Blotting (WB) at a recommended dilution range of 1:500-1:3000

• Enzyme-Linked Immunosorbent Assay (ELISA) at a recommended dilution of 1:10000

This polyclonal antibody has been tested and confirmed to react with human, mouse, and rat samples, making it suitable for comparative studies across these species .

What is the proper storage protocol to maintain antibody activity?

For optimal performance, the MAPK1/MAPK3 (Ab-205/222) Antibody should be stored at -20°C for long-term preservation . For short-term use (less than one month), storage at 4°C is acceptable . The antibody is supplied in liquid form in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide as preservatives . Repeated freeze-thaw cycles should be avoided to prevent degradation of the antibody and loss of activity . Under proper storage conditions, the antibody maintains activity for approximately 12 months from the date of receipt .

What are the recommended protocols for using this antibody in Western blotting?

For optimal Western blotting results with MAPK1/MAPK3 (Ab-205/222) Antibody, follow this methodological approach:

• Sample preparation:

  • Prepare cell/tissue lysates in appropriate lysis buffer containing protease and phosphatase inhibitors

  • Determine protein concentration using DC Protein Assay Kit or equivalent

• SDS-PAGE separation:

  • Load 20-50 μg of protein per lane on a 12% SDS-PAGE gel

  • Include both phosphorylated and non-phosphorylated controls

• Protein transfer:

  • Transfer proteins to PVDF membrane using standard protocols

• Immunostaining procedure:

  • Block membrane with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

  • Incubate with MAPK1/MAPK3 (Ab-205/222) Antibody at a dilution of 1:500-1:3000 in blocking buffer overnight at 4°C

  • Wash 3-5 times with TBST

  • Incubate with appropriate HRP-conjugated secondary antibody (anti-rabbit IgG-HRP) at 1:2500 dilution for 1 hour at room temperature

  • Wash 3-5 times with TBST

  • Develop using chemiluminescent substrates such as SuperSignal West Femto Maximum Sensitivity Substrate or SuperSignal West Pico Chemiluminescent Substrate

  • Detect signals using a chemiluminescence imaging system

Research has shown that phosphorylation levels should be calculated as the ratio between signals from phosphorylated and total forms of ERK1/2, with β-actin used as a reference to ensure that the total amount of kinases does not change during experimental manipulation .

How should I design controls for experiments using this antibody?

Proper experimental controls are essential for validating results with the MAPK1/MAPK3 (Ab-205/222) Antibody:

• Positive controls:

  • Cell lines known to express high levels of MAPK1/MAPK3 (e.g., A549 cells, MCF-7 cells, Jurkat cells)

  • Cells treated with activators of the MAPK pathway such as phorbol esters or growth factors

• Negative controls:

  • Primary antibody omission control

  • Isotype control (non-specific rabbit IgG)

  • Cells with MAPK1/MAPK3 knockdown via siRNA

• Phosphorylation-specific controls:

  • Samples treated with phosphatase to remove phosphorylation

  • Samples treated with inhibitors of the pathway (e.g., MEK inhibitors)

  • Comparison with antibodies specific to non-phosphorylated MAPK1/MAPK3

In published research, MAPK1/MAPK3 knockdown experiments have demonstrated significant loss of migratory capacity in various cell types, including MCF-7 and Jurkat cells, confirming the specificity and utility of targeting these proteins in functional studies .

How can I use this antibody to investigate the role of MAPK1/MAPK3 in cell migration?

Cell migration studies using MAPK1/MAPK3 (Ab-205/222) Antibody can follow these methodological approaches:

• Chemotaxis migration assay:

  • Use ChemoTX plates to measure directional cell migration

  • Apply CXCL12 or other chemoattractants as migration stimuli

  • Quantify migration after treatment with MAPK pathway activators or inhibitors

  • Compare MAPK1/MAPK3 phosphorylation status with migration capacity

• Transwell migration assay:

  • Utilize Boyden Chamber assays to assess vertical migration

  • Apply fluorescence-based quantification methods

  • Compare control cells with those expressing mutated forms of MAPK1/MAPK3

• Wound healing assay:

  • Create a scratch in a cell monolayer

  • Monitor wound closure over time with brightfield microscopy

  • Quantify migration by measuring the area of wound closure

  • Correlate with MAPK1/MAPK3 activation status using the antibody

Research has shown that arrestin-3 overexpression can significantly increase migration of Jurkat cells via CXCR4 upon CXCL12 activation, with this effect being dependent on MAPK signaling pathways . Figure 5.17 from published research demonstrates the effects of arrestin-3 overexpression on chemotaxis assays involving PKC and MAPK pathways, highlighting the interconnected nature of these signaling cascades in cellular migration .

What are the considerations for detecting MAPK1/MAPK3 activation in response to different stimuli?

When investigating MAPK1/MAPK3 activation in response to various stimuli, consider these methodological approaches:

• Temporal dynamics:

  • Establish a time course (5, 15, 30, 60 minutes) after stimulus application

  • Monitor both rapid and sustained activation phases

  • Compare phosphorylation kinetics across different stimuli

• Cell-type specific responses:

  • Different cell types show varying patterns of MAPK1/MAPK3 activation

  • Neuronal cells: Ouabain induced changes in ERK1/2 phosphorylation are detectable and quantifiable using specific antibodies against phospho-ERK1/2

  • Cancer cells: MCF-7 breast cancer cells show distinct MAPK1/MAPK3 activation patterns compared to leukemic T lymphocytes (Jurkat cells)

• Stimulus-specific protocols:

  • For ouabain and other cardiotonic steroids: Concentrations of 1-100 nM for 5-30 minutes

  • For chemokines (CXCL12): 10 nM concentration for detection of downstream MAPK activation

  • For glucocorticoids: 100 nM dexamethasone treatment for 1-24 hours

• Quantification methods:

  • Use densitometry to calculate phospho-MAPK1/MAPK3 to total MAPK1/MAPK3 ratio

  • Analyze data using appropriate statistical tests (ANOVA with post-hoc tests)

  • Report both p-values and q-values (difference between two means divided by standard error)

Research has demonstrated that in neuronal progenitors, ouabain treatment activates intracellular signaling pathways including MAPK (ERK1/2, p38, JNK), IP3K, PKC, and Akt, which can be effectively detected using phospho-specific antibodies .

How can I investigate interactions between MAPK1/MAPK3 and cytoskeletal dynamics?

To study MAPK1/MAPK3 interactions with the cytoskeleton, employ these methodological approaches:

• Live-cell imaging of cytoskeletal networks:

  • Use fluorescently tagged cytoskeletal proteins (e.g., GFP-tagged EB3 for microtubule dynamics)

  • Track microtubule growth speed in response to pathway activation

  • Analyze the impact of MAPK1/MAPK3 inhibition on cytoskeletal remodeling

• Actin polymerization studies:

  • Use phalloidin staining to visualize actin structures

  • Assess localized actin assembly versus receptor desensitization

  • Correlate MAPK1/MAPK3 activation with actin polymerization patterns

• Migration-cytoskeleton correlation:

  • Monitor microtubule dynamics during cell migration

  • Analyze fast, medium, and slow speed events in microtubule growth

  • Measure changes in median speed of microtubule growth in response to MAPK pathway activation

What are common pitfalls in phospho-MAPK1/MAPK3 detection and how can they be avoided?

When working with MAPK1/MAPK3 (Ab-205/222) Antibody for phosphorylation studies, be aware of these common challenges:

• Sample preparation issues:

  • Problem: Rapid dephosphorylation during cell lysis

  • Solution: Use phosphatase inhibitors in lysis buffers; maintain samples at 4°C during processing; process samples rapidly

• Signal specificity concerns:

  • Problem: Cross-reactivity with other phosphorylated proteins

  • Solution: Include phospho-knockout controls; use multiple antibodies targeting different epitopes; validate with phosphatase treatment

• Reproducibility challenges:

  • Problem: Variable activation levels between experiments

  • Solution: Standardize cell culture conditions; use consistent stimulation protocols; control for cell density and passage number

• Signal quantification issues:

  • Problem: Difficulty distinguishing signal from background

  • Solution: Optimize antibody dilutions (1:500-1:3000); increase washing steps; use enhanced chemiluminescence detection systems

Research comparing MAPK1/MAPK3 activation across cell types has demonstrated that activation of signaling molecules needed for CXCL12-induced migration can differ significantly between different cell lines, emphasizing the importance of optimizing detection methods for each experimental system .

How can I validate the specificity of MAPK1/MAPK3 (Ab-205/222) Antibody in my experimental system?

To confirm antibody specificity in your experimental system, employ these methodological approaches:

• Gene silencing validation:

  • Perform siRNA-mediated knockdown of MAPK1/MAPK3

  • Western blot comparison between control and knockdown samples

  • Quantify reduction in signal with densitometry analysis

• Phosphorylation site validation:

  • Test antibody against samples with known mutations at Y222/Y205 sites

  • Compare signals from wild-type and phospho-mutant proteins

  • Use phosphatase treatment to remove phosphorylation

• Peptide competition assay:

  • Pre-incubate antibody with the immunizing peptide

  • Compare signal between blocked and unblocked antibody

  • Reduction in signal confirms epitope specificity

• Cross-species reactivity testing:

  • Test antibody against samples from multiple species (human, mouse, rat)

  • Compare signal intensity and pattern across species

  • Adjust protocols based on species-specific optimization

In published research, MAPK1/MAPK3 siRNA knockdown experiments showed significant loss of CXCL12-induced migration in both chemically transfected MCF-7 cells and electroporation transfected Jurkat cells, confirming the functional specificity of targeting these proteins .

How can I use this antibody to investigate MAPK1/MAPK3 involvement in complex disease models?

For studying MAPK1/MAPK3 in disease models, consider these methodological approaches:

• Cancer research applications:

  • Analyze MAPK1/MAPK3 activation in relation to tumor mutation burden

  • Correlate with other pathways (e.g., PIK3CA mutations in breast cancer)

  • Study combined inhibition of MAPK pathway with other therapeutically relevant targets

• Neurodegenerative disease models:

  • Investigate MAPK1/MAPK3 activation in iPSC-derived neurons

  • Study effects of disease-specific stimuli on phosphorylation patterns

  • Correlate with changes in cellular function and viability

• Autism spectrum disorder research:

  • Examine MAPK1/MAPK3 signaling across different autism subtypes

  • Analyze pathway dysregulation in relation to symptom heterogeneity

  • Consider MAPK1/MAPK3 as potential biomarkers for distinct autism phenotypes

Research has suggested that autism is unlike a single disorder in various ways—no single brain deficit causes it, no single drug affects it, and no single cause or cure has been found . Investigating molecular pathways such as MAPK1/MAPK3 signaling may help parse the different biological mechanisms underlying symptom constellations, potentially leading to more personalized treatment approaches.

What methodologies can I use to study the spatiotemporal dynamics of MAPK1/MAPK3 activation?

To investigate spatiotemporal aspects of MAPK1/MAPK3 signaling, implement these advanced approaches:

• Live-cell imaging techniques:

  • Use fluorescently tagged proteins (e.g., HaloTag-GR) to track protein movement

  • Monitor translocation events in response to stimuli

  • Quantify displacement and step length parameters for dynamic analysis

• BRET (Bioluminescence Resonance Energy Transfer) assays:

  • Measure protein-protein interactions in real-time

  • Detect conformational changes during MAPK1/MAPK3 activation

  • Monitor kinetics of interaction with upstream and downstream partners

• Subcellular fractionation studies:

  • Separate nuclear and cytoplasmic fractions

  • Compare phospho-MAPK1/MAPK3 distribution across compartments

  • Track translocation kinetics after stimulation

Research using live-cell imaging has revealed that glucocorticoids can rapidly inhibit cell migration through non-genomic mechanisms involving changes in microtubule dynamics. These effects can be quantified by measuring total displacement (μm) and median step length (μm) of cells, revealing significant differences between control and treated conditions (p<0.0001) .

Table derived from data in search result showing the impact of glucocorticoid treatment on cell migration parameters

How might single-cell analysis techniques enhance our understanding of MAPK1/MAPK3 signaling heterogeneity?

Single-cell analysis offers powerful new approaches for MAPK1/MAPK3 research:

• Single-cell phospho-proteomics:

  • Analyze cell-to-cell variation in MAPK1/MAPK3 activation states

  • Identify rare cell populations with distinct signaling profiles

  • Correlate with cell fate decisions and functional outcomes

• Spatial transcriptomics integration:

  • Combine MAPK1/MAPK3 activity measurements with gene expression analysis

  • Map pathway activation to transcriptional responses at single-cell resolution

  • Identify microenvironmental factors influencing signaling heterogeneity

• Multi-parameter flow cytometry:

  • Simultaneously measure multiple phosphorylated signaling proteins

  • Create high-dimensional maps of intracellular signaling networks

  • Identify coordinated regulation of MAPK1/MAPK3 with other pathways

Research examining the effects of exogenous phytase on growth performances and meat quality has utilized real-time quantitative PCR to determine the expression of target genes, including MAPK1, MAPK3, MAPK8, and MAPK14, demonstrating the applicability of molecular techniques for analyzing MAPK pathway components in complex biological systems .

What are the emerging techniques for studying MAPK1/MAPK3 in the context of protein-protein interaction networks?

Advanced methodologies for investigating MAPK1/MAPK3 interaction networks include:

• Proximity labeling approaches:

  • Use BioID or APEX2 techniques to identify proteins in close proximity to MAPK1/MAPK3

  • Map dynamic changes in interaction networks following stimulation

  • Discover new pathway components and regulatory mechanisms

• Protein complementation assays:

  • Split fluorescent proteins to detect direct protein-protein interactions

  • Monitor association/dissociation kinetics in live cells

  • Map interaction domains through mutagenesis studies

• Cryo-electron microscopy:

  • Visualize MAPK1/MAPK3 complexes at near-atomic resolution

  • Determine structural changes associated with phosphorylation

  • Identify binding interfaces for therapeutic targeting

Research has shown that arrestins can scaffold for MAPK signaling, with arrestin 3 playing a significant role in migration of Jurkat cells via CXCR4 upon CXCL12 activation . Understanding these protein interaction networks has important implications for developing therapeutics targeting MAPK1/MAPK3 in various disease contexts.